Evidence map›Paper›PMID 30793240›Full record

ArticleMolecular imaging and biology2019

(2S,4R)-4-[

Hua Zhu, Fei Liu, Yan Zhang, Jianhua Yang, Xiaoxia Xu, Xiaoyi Guo, Teli Liu, Nan Li, Lin Zhu, Hank F Kung and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. KRAS Mutation Detection with (2Molecular pharmaceutics · 2024
    Article
  2. Article
  3. [Frontiers in oncology · 2021
    Article
  4. Review
  5. Dynamic PET/CT imaging ofEuropean journal of nuclear medicine and molecular imaging · 2020
    Article
  6. Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.Cellular and molecular gastroenterology and hepatology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hua ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Fei LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Yan ZhangKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Jianhua YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaoxia XuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaoyi GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Teli LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Nan LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Lin ZhuKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Hank F KungCapital Medical University, Beijing Institute for Brain Diseases, Beijing, 100069, China. kunghf@gmail.com.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China. pekyz@163.com.
Peking University Cancer Hospital · CNPeking University · CNBeijing Normal University · CNChinese Institute for Brain Research · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrevious reports confirmed that (2S,4R)-4-[ PROCEDURES: Bone marrow inhibition model in mice was induced by an intravenous injection of chemotherapy drug (doxorubicin or rituximab) and the inhibition was confirmed by routine blood cell counts. Bone uptakes of these four radiotracers (2-deoxy-2-[

results[

conclusionsDissection experiments in mice showed that [

trial registrationApproved by Institutional Review Board of Peking University Cancer Hospital (No. 2017KT38). Registered 18 August 2017.

Indexed as

Positron-Emission TomographyAgedAnimalsBone MarrowFemaleGlutamineHumansMaleMiceMiddle AgedPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTime FactorsTissue DistributionWhole Body Imaging4-fluoroglutamineGlutamineRadiopharmaceuticals(2S,4R)-4-[18F]fluoroglutamineBone marrowGlutamine metabolic imagingMyelosuppression

Identifiers

PMID30793240
OpenAlexW2916819389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.